Abstract:Hepatic fibrosis is an essential pathology of multiple chronicliverdiseases. The aim of this study was to investigate the role of miR-301a-3p in hepatic fibrosis. We found that miR-301a-3p was upregulated in hepatic fibrosis patients and in culture-activated human hepatic stellate cells (HSCs). Interestingly, miR-301a-3p expression was increased in hepatic fibrosis progression mice while decreased in hepatic fibrosis recovery mice, indicating that miR-301a-3p may participate in the hepatic fibrosis pathology. Functionally, the effects of miR-301a-3p both on hepatic fibrosis progression and regression were assessed in vivo. Inhibiting miR-301a-3p amelioratedmouse liver fibrogenesis and collagen deposition and suppressed HSC activation and fibrogenic factor expression. Whereas, in hepatic fibrosis regression, upregulating miR-301a-3p impaired mouse hepatic fibrosis recovery by inducing HSC activation and triggering inflammation. Consistently, gain-of-function and loss-of-function analysis of miR-301a-3p were performed to evaluate its effects on human HSCs LX-2 cell. We found that suppressing miR-301a-3p inhibited LX-2 cell activation and proliferation, and induced LX-2 cell apoptosis, accompaniedby decreased fibrotic mediators expression. Collectively, these findings suggest miR-301a-3p drives liver fibrogenesis and HSC activation in hepatic fibrosis. Mechanistically, we demonstrated miR-301a-3p binds directly to phosphatase and tensin homolog (PTEN) by luciferase reporter analysis, pull-down, and RIP assay. Indicating that miR-301a-3p plays a critical rolein promotingliverfibrogenesis viamodulating the PTEN/platelet derived growth factor β (PDGFR-β) pathway. In conclusion, our findings demonstrate that miR-301a-3p expression is closely correlated with hepatic fibrosis pathology, and that enhancing miR-301a-3p maintains the HSC profibrogenic phenotype, triggers inflammatoryresponses, promotes fibrogenic factor production, and further exacerbates liver fibrogenesis. These findings suggest that miR-301a-3p may serve as a promising diagnostic and prognosis biomarker for hepatic fibrosis treatment.

Mir-488-5p Mitigates Hepatic Stellate Cell Activation and Hepatic Fibrosis Via Suppressing TET3 Expression

Mir-301A-3p Promotes Hepatic Stellate Cells Activation and Liver Fibrogenesis Via Regulating PTEN/PDGFR-β.

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

MicroRNA-101 Suppresses Liver Fibrosis by Downregulating PI3K/Akt/mTOR Signaling Pathway

Mir-345–5P Curbs Hepatic Stellate Cell Activation and Liver Fibrosis Progression by Suppressing Hypoxia-Inducible Factor-1Alpha Expression

Mir-140-3p Knockdown Suppresses Cell Proliferation and Fibrogenesis in Hepatic Stellate Cells Via PTEN-Mediated AKT/mTOR Signaling.

miR-140-5p attenuates hepatic fibrosis by directly targeting TGFβR1

Mir-185 Inhibits Fibrogenic Activation of Hepatic Stellate Cells and Prevents Liver Fibrosis.

Downregulation of Mir-20B-5p Contributes to the Progression of Liver Fibrosis Via the STAT3 Signaling Pathway in Vivo and in Vitro

MicroRNA-378 Limits Activation of Hepatic Stellate Cells and Liver Fibrosis by Suppressing Gli3 Expression

Inhibition of miR‐188‐5p alleviates hepatic fibrosis by significantly reducing the activation and proliferation of HSCs through PTEN/PI3K/AKT pathway

MicroRNA-146b Regulates Hepatic Stellate Cell Activation Via Targeting of KLF4.

MiR-22-3p and Mir-29A-3p Synergistically Inhibit Hepatic Stellate Cell Activation by Targeting AKT3

MicroRNA-489-3p Represses Hepatic Stellate Cells Activation by Negatively Regulating the JAG1/Notch3 Signaling Pathway

MicroRNA-195-3p promotes hepatic stellate cell activation and liver fibrosis by suppressing PTEN expression

Mir-654-5p Contributes to the Activation and Proliferation of Hepatic Stellate Cells by Targeting RXRα

Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling

MicroRNA-30 Protects Against Carbon Tetrachloride-induced Liver Fibrosis by Attenuating Transforming Growth Factor Beta Signaling in Hepatic Stellate Cells

The miR-23b/27b/24-1 Cluster Inhibits Hepatic Fibrosis by Inactivating Hepatic Stellate Cells

MicroRNA-134 Deactivates Hepatic Stellate Cells by Targeting TGF-β Activated Kinase 1-Binding Protein 1.

MicroRNA-212 activates hepatic stellate cells and promotes liver fibrosis via targeting SMAD7.